Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients
Open Access
- 31 January 2019
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 102 (2), 111-122
- https://doi.org/10.1111/ejh.13193
Abstract
The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early development of progressive arthropathy, alongside higher treatment-related costs. Bypassing agents can be used to prevent and control bleeding, as well as the recently licensed prophylaxis, emicizumab, but their efficacy is less predictable than that of factor replacement therapy. Antibody eradication, by way of immune tolerance induction (ITI), is still the preferred management strategy for treating patients with inhibitors. This approach is successful in most patients, but some are difficult to tolerise and/or are unresponsive to ITI, and they represent the most complicated patients to treat. However, there are limited clinical data and guidelines available to help guide physicians in formulating the next treatment steps in these patients. This review summarises currently available treatment options for patients with inhibitors, focussing on ITI regimens and those ITI strategies that may be used in difficult-to-treat patients. Some alternative, non-ITI approaches for inhibitor management, are also proposed.Keywords
Funding Information
- Novo Nordisk
This publication has 92 references indexed in Scilit:
- The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?Haemophilia, 2012
- Health‐related quality of life in haemophilia patients with inhibitors and their caregiversHaemophilia, 2012
- Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practiceEuropean Journal of Haematology, 2012
- Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitorsHaemophilia, 2009
- Immune tolerance induction with mycophenolate‐mofetil in two children with haemophilia B and inhibitorHaemophilia, 2007
- European Study on Orthopaedic Status of haemophilia patients with inhibitorsHaemophilia, 2007
- Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experienceHaemophilia, 2007
- Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society RegistryHaemophilia, 2005
- Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’Vox Sanguinis, 1996
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIIThe New England Journal of Medicine, 1988